Adenofibroma: A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)Cystadenofibroma: Benign or borderline malignant neoplasm of the ovary and surrounding tissues. It is characterized by tumor(s) with cystic glands which are lined by cuboidal EPITHELIAL CELLS with clear cytoplasm, resembling ENDOMETRIUM cells. The glands are separated by fibroblastic STROMAL CELLS.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Dictionaries, ChemicalCarcinosarcoma: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Carcinoma 256, Walker: A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)Uterine Neoplasms: Tumors or cancer of the UTERUS.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.National Cancer Institute (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.United StatesNational Institutes of Health (U.S.): An operating division of the US Department of Health and Human Services. It is concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research. Until 1995, it was an agency of the United States PUBLIC HEALTH SERVICE.T-Lymphocytes, Regulatory: CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.Forkhead Transcription Factors: A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila.Disclosure: Revealing of information, by oral or written communication.Truth Disclosure: Truthful revelation of information, specifically when the information disclosed is likely to be psychologically painful ("bad news") to the recipient (e.g., revelation to a patient or a patient's family of the patient's DIAGNOSIS or PROGNOSIS) or embarrassing to the teller (e.g., revelation of medical errors).Interleukin-2 Receptor alpha Subunit: A low affinity interleukin-2 receptor subunit that combines with the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN to form a high affinity receptor for INTERLEUKIN-2.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.T-Lymphocyte Subsets: A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Nephrectomy: Excision of kidney.Atlases as Topic: Collections of illustrative plates, charts, etc., usually with explanatory captions.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Adenosarcoma: A malignant neoplasm arising simultaneously or consecutively in mesodermal tissue and glandular epithelium of the same part. (Stedman, 25th ed)Endometrial Stromal Tumors: Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain cells that may closely or remotely resemble the normal stromal cells. Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or endolymphatic stromal myosis; and (3) malignant endometrial stromal sarcoma (SARCOMA, ENDOMETRIAL STROMAL).Gestational Trophoblastic Disease: A group of diseases arising from pregnancy that are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread.Smooth Muscle Tumor: A tumor composed of smooth muscle tissue, as opposed to leiomyoma, a tumor derived from smooth muscle.Trophoblastic Neoplasms: Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691)Ovarian Cysts: General term for CYSTS and cystic diseases of the OVARY.Dermoid Cyst: A tumor consisting of displaced ectodermal structures along the lines of embryonic fusion, the wall being formed of epithelium-lined connective tissue, including skin appendages, and containing keratin, sebum, and hair. (Stedman, 25th ed)Cysts: Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.Follicular Cyst: Cyst due to the occlusion of the duct of a follicle or small gland.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Ibuprofen: A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis.Cyst Fluid: Liquid material found in epithelial-lined closed cavities or sacs.Bibliometrics: The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)Publications: Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181)Christianity: The religion stemming from the life, teachings, and death of Jesus Christ: the religion that believes in God as the Father Almighty who works redemptively through the Holy Spirit for men's salvation and that affirms Jesus Christ as Lord and Savior who proclaimed to man the gospel of salvation. (From Webster, 3d ed)Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Pelger-Huet Anomaly: Autosomal dominant anomaly characterized by abnormal ovoid shape GRANULOCYTE nuclei and their clumping chromatin. Mutations in the LAMIN B receptor gene that results in reduced protein levels are associated with the disorder. Heterozygote individuals are healthy with normal granulocyte function while homozygote individuals occasionally have skeletal anomalies, developmental delay, and seizures.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Hysteroscopes: Endoscopes for examining the interior of the uterus.RNA, Double-Stranded: RNA consisting of two strands as opposed to the more prevalent single-stranded RNA. Most of the double-stranded segments are formed from transcription of DNA by intramolecular base-pairing of inverted complementary sequences separated by a single-stranded loop. Some double-stranded segments of RNA are normal in all organisms.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Nucleic Acid Conformation: The spatial arrangement of the atoms of a nucleic acid or polynucleotide that results in its characteristic 3-dimensional shape.RNA: A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed)Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.RNA, Viral: Ribonucleic acid that makes up the genetic material of viruses.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. (1/127)
The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells, especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely unknown. We have investigated the presence of C/EBPalpha, -beta, -delta and -zeta in normal ovaries and in epithelial ovarian tumours of different stages. Immunohistochemical experiments demonstrated that C/EBPalpha and C/EBPbeta were preferentially expressed in epithelial/tumour cells irrespective of stage or grade of the tumour. C/EBPbeta was located in the nuclei of the cells, in contrast to C/EBPalpha, which was present only in the cytoplasm of these cells. The nuclear localization of C/EBPbeta indicates an active role of this transcription factor in tumour cells, whereas the cytoplasmic distribution suggests a more passive function of C/EBPalpha. C/EBPdelta and -zeta demonstrated a more diverse distribution with predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the nucleus and the cytoplasm for C/EBPdelta and -zeta. Western blotting demonstrated that C/EBPalpha, -beta, -delta and -zeta were present in a majority of the samples. The amount of C/EBPbeta increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPbeta as a potential marker for these tumours. As C/EBPbeta is known to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and play a central role in tumour progression. (+info)In vitro estrogen-binding by human breast carcinomas. (2/127)
Patients whose breast carcinomas possess only low concentrations of a receptor molecule that binds estrogens with high affinity are unlikely to respond to hormonal manipulative therapy when the disease recurs. The estrogen-binding capacity of 106 breast carcinomas was measured by an in vitro method and was expressed per milligram wet weight and in some cases related to the concentration of deoxyribonucleic acid (DNA) of the tumours. The ability of tumors to bind 3H-estradiol ranged from 0 to 1.3 fm/mg in pre- and perenopausal women, and from 0 to 16.8 fm/mg in postmenopausal women. Menopausal status or serum concentrations of endogenous estrogen, or both, should therefore be considered when tumours are classified into low and high estrogen-binding capacity. It is not necessary to carry out Scatchard analysis for every tumour, and expressing estradiol binding on the basis of DNA concentration may be preferable to expressing in on a wet-weight basis. (+info)Serous adenocarcinofibroma of the ovary--report of two cases and review of the literature. (3/127)
We investigated the clinical and histologic characteristics of patients with ovarian serous adenocarcinofibroma. Because the tumors in both cases contained fibroma components; they were hard and clinically indistinguishable from uterine myoma, even by computed tomography. Both patients experienced relapses associated with tumors that originated outside the abdominal cavity (the subcutaneous abdominal wall in case 1, and the inguinal lymph nodes in case 2). The serum level of CA125 was normal or only moderately elevated at the first onset and relapse. The present cases suggest that the diagnostic features and clinical course differ between ovarian serous adenocarcinoma and serous adenocarcinofibroma. (+info)Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. (4/127)
The DNA base excision repair pathway is responsible for the repair of alkylation and oxidative DNA damage. A crucial step in the base excision repair pathway involves the cleavage of an apurinic/apyrimidinic (AP) site in DNA by an AP endonuclease (APE). The major AP endonuclease in mammalian cells is APE/ref-1, a multifunctional enzyme that acts not only as an AP endonuclease but as a redox-modifying factor for a variety of transcription factors. The purpose of this study was to determine the expression of APE/redox factor-1 (ref-1) in ovarian tissues, particularly ovarian cancers. Formalin-fixed, paraffin-embedded specimens of ovarian tissues (normal, various benign conditions, and epithelial cancers) were studied using both polyclonal and monoclonal antibodies to APE/ref-1. The relationship between APE/ref-1 protein levels and DNA repair activity was studied in ovarian Hey and Hey-C2 cell lines using Western blot and a specific AP-site oligonucleotide cleavage assay. Hey and Hey-C2 cells were fractionated, and the nuclear and cytoplasmic extracts were quantitated for protein levels and assessed for APE/ref-1 with Western blot. Normal ovarian tissues consistently demonstrated strong nuclear staining of the surface epithelium, epithelial inclusions, corpora lutea and albicantia, and stroma. Cytoplasmic staining was absent. A similar pattern was seen for benign conditions including endometriosis. Low malignant potential ovarian cancers stained in a pattern similar to normal ovarian and nonneoplastic tissues; however, two specimens also had areas of cytoplasmic staining. Epithelial ovarian cancers were remarkably different from all other ovarian tissues studied. Both nuclear and cytoplasmic staining of the malignant epithelium were seen and ranged from strong to weak, often with considerable staining heterogeneity within the same tumor. The AP-site oligonucleotide cleavage assay indicated that APE/ref-1 protein levels correlate well with DNA repair activity. The increased levels of APE/ref-1 in the Hey-C2 cells was mainly attributable to increased cytoplasmic enzyme. APE/ref-1 immunoreactivity is altered in malignant ovarian tumors. Further studies will determine whether the altered expression and subcellular location reflect changes in redox regulatory functions. (+info)Accumulation of collagen in ovarian benign tumours. (5/127)
Extracellular matrix components of benign ovarian tumours (cystadenoma, adenofibroma, cystadenofibroma) were analysed. The investigated tumours contained twice as much collagen than control ovarian tissues. Significant alterations in mutual quantitative relationships between collagens of various types were observed. The proportion of type I collagen decreased and that of type III collagen increased. The accumulation of collagen was accompanied by a reduction in sulphated glycosaminoglycan content whereas the amount of hyaluronic acid was not changed. Dermatan sulphate was the most abundant glycosaminoglycan component. It is suggested that the accumulation of collagen (natural barrier to the migration of tumour cells) and underexpression of glycosaminoglycans/proteoglycans (binding some growth factors and interleukins) may exert an inhibitory effect on tumour growth. (+info)Contrast-enhanced sonography in the examination of benign and malignant adnexal masses. (6/127)
Our objective was to characterize the properties of an intravascular ultrasonographic contrast agent in examination of adnexal masses and to compare contrast agent properties between benign and malignant adnexal tumors. Fifty-eight consecutively examined women with suspected ovarian tumors were examined preoperatively by power Doppler ultrasonography, first without and then with contrast agent enhancement (Levovist). Fourteen women had ovarian cancer, 3 had borderline ovarian tumors, 18 had benign ovarian neoplasms, and 23 had functional adnexal cystic masses or endometriomas. The effect of the contrast agent was evaluated visually and by using computerized power Doppler signal intensity measurements. In visual evaluation, the brightness of the power Doppler signal and the amount of recognizable vascular areas increased in each tumor after contrast agent administration. The number of vessels in power Doppler ultrasonograms, both before and after contrast agent enhancement, was significantly higher in malignant than in benign adnexal masses, as also was the increase in the number of recognizable vessels after contrast agent administration. Contrast agent uptake time was significantly shorter in malignant than in benign tumors. No significant differences were found in the power Doppler signal intensities or their changes between benign and malignant tumors. In conclusion, use of sonographic contrast agent facilitates imaging of tumor vessels. For differentiation of benign and malignant tumors, the kinetic properties of the contrast agent, such as uptake and washout times, may have more potential than the use of the contrast agent in anatomic imaging of the tumor vessels. (+info)Apparent rat strain-related sensitivity to phorbol promotion of mammary carcinogenesis. (7/127)
It has been reported that twice-weekly i.p. injections of 4 mg phorbol for 10 weeks, after a single feeding of 6 mg dimethylbenz(a)anthracene (DMBA) in female Wistar rats, led to a significant augmentation of mammary adenocarcinoma incidence and of lymphatic leukemia incidence as compared to 6 mg DMBA alone. In an experiment reported here, in female Sprague-Dawley rats, using the same doses of DMBA and phorbol and the same injection schedule, phorbol given after DMBA did not augment mammary adenocarcinoma incidence or lymphatic leukemia incidence as compared to DMBA given alone. It thus appears that there is a strain-related sensitivity between Wistar and Sprague-Dawley rats with regard to the promoting activity of phorbol when phorbol treatment follows DMBA treatment, and mammary adenocarcinoma incidence and lymphatic leukemia incidence are studied. Further, in Sprague-Dawley rats, phorbol did not promote mammary fibroadenoma incidence in DMBA-treated rats, mammary adenocarcinoma incidence in procarbazine-treated rats, and mammary adenocarcinoma incidence or mammary fibroadenoma incidence in X-ray-treated rats. DMBA and procarbazine, with or without phorbol, tended to induce more mammary neoplasms in the anterior (thoracic) than in the posterior (abdominal) mammary glands. X-irradiation tended to induce mammary neoplasms in approximately equal numbers in the anterior and posterior mammary glands. It was suggested that regional differences in chemically induced mammary carcinogenesis were due to a difference in the transport and delivery of the chemical carcinogens to the regions rather than a difference in the amount of mammary gland tissue in the regions. An analysis of the numbers of Sprague-Dawley rats that developed either no mammary neoplasms, or only mammary adenocarcinomas, or only mammary fibroadenomas, or both mammary adenocarcinomas and mammary fibroadenomas in response to DMBA, procarbazine, and X-ray, suggested that the development of a mammary adenocarcinoma or the development of a mammary fibroadenoma are independent processes. (+info)Sonographic features of ovarian cystadenofibromas: spectrum of findings. (8/127)
OBJECTIVE: To describe the sonographic characteristics of ovarian cystadenofibromas. METHODS: We conducted a retrospective study of 23 ovarian tumors histopathologically confirmed as ovarian cystadenofibromas that were preoperatively evaluated by transvaginal color Doppler sonography. RESULTS: In all cases the mass was predominantly cystic. Septations appeared in 30.4% of the tumors. Papillary projections or solid nodules appeared in 56.5% of the cases. The most frequent appearance was a unilocular complex cystic mass. In 47.8% of the tumors, vascularization was detected, having a typical pattern of peripheral vascularization with scattered vessels of high blood flow impedance. CONCLUSIONS: We have described the sonographic spectrum of findings of ovarian cystadenofibromas. The most frequent appearance was a unilocular cystic mass with gross papillary projections or solid nodules. In almost half of the tumors, vascularization could be detected. (+info)... adenofibroma MeSH C04.557.450.565.590.595.150 --- brenner tumor MeSH C04.557.450.565.590.595.350 --- fibroadenoma MeSH C04.557. ... adenofibroma MeSH C04.557.470.625.150 --- brenner tumor MeSH C04.557.470.625.350 --- fibroadenoma MeSH C04.557.470.660 --- ...
... ovarian cyst Dermoid cyst Ovarian serous cystadenoma Ovarian mucinous cystadenoma Paraovarian cyst Cystic adenofibroma ...
NOS Papillary adenofibroma M9014/0 Serous adenofibroma, NOS Serous cystadenofibroma, NOS M9014/1 Serous adenofibroma of ... Malignant serous adenofibroma Serous cystadenocarcinofibroma Malignant serous cystadenofibroma M9015/0 Mucinous adenofibroma, ... NOS M8964/3 Clear cell sarcoma of kidney M8965/0 Nephrogenic adenofibroma M8966/0 Renomedullary interstitial cell tumor ... clear cell cystadenofibroma M8313/1 Clear cell adenofibroma of borderline malignancy Clear cell cystadenofibroma of borderline ...
What is adenofibroma edematodes? Meaning of adenofibroma edematodes medical term. What does adenofibroma edematodes mean? ... Looking for online definition of adenofibroma edematodes in the Medical Dictionary? adenofibroma edematodes explanation free. ... adenofibroma edematodes. adenofibroma edematodes. a neoplasm consisting of glandular elements and connective tissue in which ... Adenofibroma edematodes , definition of adenofibroma edematodes by Medical dictionary https://medical-dictionary. ...
Adenofibroma definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up ...
... N. Thao T. Nguyen,1 Theresa R. Harring,1 Laurie Holley,2 John ... N. Thao T. Nguyen, Theresa R. Harring, Laurie Holley, John A. Goss, and Christine A. OMahony, "Biliary Adenofibroma with ...
MalaCards based summary : Adenofibroma, also known as adenofibroma, no icd-o subtype, is related to clear cell adenofibroma and ... Diseases in the Adenofibroma family:. Malignant Adenofibroma Diseases related to Adenofibroma via text searches within ... MalaCards organs/tissues related to Adenofibroma:. 38 Ovary, Cervix, Uterus, Lung, Testis, Breast, Liver ... Articles related to Adenofibroma:. (show top 50) (show all 122) #. Title. Authors. Year. ...
Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian ... clear-cell adenofibroma-associated pathway. Virchows Arch. 2009;455:261-270 74. Yamamoto S, Tsuda H, Takano M. et al. ... Adenofibroma (n=4). Atypical proliferative (borderline) tumor (n=41). Mean patient age (years) [range]. 61 (50-75). 60 (30-85) ... Clear Cell Adenofibroma (n=4). The clinicopathologic features with respect to age, stage, bilaterality, tumor size, and gross ...
Uterine Corpus Adenofibroma. Known as: Adenofibroma of Uterine Body, Corpus Uteri Adenofibroma, Adenofibroma of Uterine Corpus ... Endometrial adenofibroma].. *Khedija Bellil, Slim Haouet, Carole Goutallier Ben Fadhel, Nidhaeddine Kchir, Dalenda Chelli, ... Uterine cervical adenofibroma associated with Turners syndrome in a young woman. *Osamu Ishiko, Toshiyuki Sumi, Kayoko Ueda, ... Paratesticular adenofibroma is an uncommon benign tumour. Although it has previously been reported in the female reproductive… ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full ... Adenofibroma. A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. ( ... Detailed information through a personalized searchRanked list of diseases related to "Adenofibroma"Drugs, active principles and ... "Adenofibroma"Medicinal plantsQuestions and answers from other usersNewsVideos ...
Papillary adenofibroma. This neoplasm is uncommon. Grossly, it appears as a polypoid structure. On ultrasound, cystic areas ... Haberal A, Cil AP, Gunes M, Cavusoglu D. Papillary adenofibroma of the cervix: A case report. Ultrasound Obstet Gynecol. Aug ...
Adenofibroma is a benign tumor composed histologically of epithelial elements and mesenchymal stroma. Carcinosarcoma is a ... Adenofibroma, Carcinosarcoma, Malignant transformation of adenofibroma, Magnetic resonance imaging. Affiliation:. Department of ... Carcinosarcoma arising from adenofibroma of the uterus has never been reported in the English literature. We report a case of a ... Imaging Features of Carcinosarcoma Arising from Adenofibroma of the Uterus: A Case Report Author(s):. Jiyun Oh, Sung Bin Park ...
Solitary fibrous pseudopapillary tumor of the lung: pulmonary fibroadenoma and adenofibroma revisited]. A Cavazza G Rossi L De ... corresponding to what has been reported in the literature as pulmonary adenofibroma and fibroadenoma. The most important ...
SEROUS ADENOFIBROMA AND CYSTADENOFIBROMA OF THE OVARY. ROTHMAN, DAVID; BLUMENTHAL, HERMAN T. ...
adenofibroma or fibroadenoma. *fatty lumps made of bruised, dead, or injured mammary fat cells ...
Diseases associated with CALB2 include Adenomatoid Tumor and Adenofibroma. GO annotations related to this gene include calcium ...
adenofibroma. *12409724. sarcomatoid mesothelioma. *malignant fibrous mesothelioma. - elite association - COSMIC cancer census ...
Adenofibroma.. -Brenners tumour:. -Over 95% are benign and more than 90% are unilateral.. They may be associated with mucinous ...
Adenofibroma.. An adenofibroma is a noncancerous development. Its generally discovered on fibrous and glandular tissue. In a ... case report of an adenofibroma of the female prostate, the growth triggered discomfort during sexual relations. Surgical ...
Abell MR (1971) Papillary adenofibroma of the uterine cervix. Am J Obstet Gynecol 110(7):990-993PubMedGoogle Scholar ... Fratini D, Cavaliere A (1996) Papillary adenofibroma of the uterine cervix: a case report. Pathologica 88(2):135-136PubMed ...
adenofibroma Background. Solid lesions of the vulva frequently occur. When they do occur, they may represent almost any ...
Metanephric tumors (metanephric adenoma, metanephric adenofibroma, metanephric stromal tumor). *Mesoblastic nephroma (cellular ...
Metanephric tumors (metanephric adenoma, metanephric adenofibroma, metanephric stromal tumor). Mesoblastic nephroma (cellular, ...
We report a case of biliary adenofibroma in a 47-year-old woman, who presented with right upper quadrant pain for several ... Biliary adenofibroma: a rare neoplasm of bile duct origin with an indolent behavior. ... that biliary adenofibroma originates from interlobular or larger bile ducts. Three years after a subtotal resection no ... biliary adenofibroma may represent a premalignant process that warrants complete resection and thorough histopathologic ...
Endometrioid adenofibroma. 252. Proliferative (borderline) endodometrioid adenofibroma. 253. Mullerian mucinous and ... Borderline clear cell adenofibroma. 259. Metastatic carcinoma to the ovary. 260. Pseudomyxoma peritonei. C. Germ Cell Tumors. ... Adenofibroma. 219. Benign epithelial hyperplasia (secretory cell outgrowths). 219A. p53 signatures 219B. Low grade serous tubal ...
6. CCC arising from clear cell adenofibroma 7. A possible novel model on molecular genetics 8. Acknowledgements 9. References 1 ...
adenofibroma, which is a benign tumor of the breast tissue. *fibrocystic breast disease, which involves painful lumps in the ...
- and three benign forms-metanephric adenoma (adenofibroma), papillary renal cell adenoma, and oncocytoma. (renalandurologynews.com)
- They belong to the metanephric family of tumors, along with metanephric adenofibroma and metanephric adenoma. (luriechildrens.org)
- Papillary adenofibroma of the uterus. (semanticscholar.org)
- An unusual case of uterine papillary adenofibroma involved by an invasive well-differentiated adenocarcinoma is reported. (semanticscholar.org)
- Abell MR (1971) Papillary adenofibroma of the uterine cervix. (springer.com)
- AKA cervical papillary adenofibroma . (librepathology.org)
- Papillary adenofibroma of the cervix: a case report. (librepathology.org)
- We describe here for the first time a case of malignant transformation of uterine endometrial adenofibroma into carcinosarcoma that was depicted as a multilocular cystic lesion with enhancing solid portions and stalk-like structure between the myometrium and endometrial mass. (currentmedicalimagingreviews.com)
- adenofibroma and cystadenofibroma, borderline, and malignant adenofibrocarcinoma and cystadenofibrocarcinoma. (jpgo.org)
- Biliary adenofibroma: a rare neoplasm of bile duct origin with an indolent behavior. (thedoctorsdoctor.com)
- Metanephric adenofibroma is a biphasic neoplasm that occurs in children and young adults. (bostwicklaboratories.com)
- Zhao C, Wu LSF, Barner R. Pathogenesis of Ovarian Clear Cell Adenofibroma, Atypical Proliferative (Borderline) Tumor, and Carcinoma: Clinicopathologic Features of Tumors with Endometriosis or Adenofibromatous Components Support Two Related Pathways of Tumor Development. (jcancer.org)
- Adenofibroma is a benign tumor composed histologically of epithelial elements and mesenchymal stroma. (currentmedicalimagingreviews.com)
- Solitary fibrous pseudopapillary tumor of the lung: pulmonary fibroadenoma and adenofibroma revisited]. (docphin.com)
- Cavazza A, Rossi G, De Marco L, Putrino I, Pellegrino S, Piana S. [Solitary fibrous pseudopapillary tumor of the lung: pulmonary fibroadenoma and adenofibroma revisited]. (docphin.com)
- We interpret this lesion as a peculiar pseudopapillary variant of solitary fibrous tumor, corresponding to what has been reported in the literature as pulmonary adenofibroma and fibroadenoma. (docphin.com)
- Diseases associated with CALB2 include Adenomatoid Tumor and Adenofibroma . (genecards.org)
- This staining pattern, similar to bile duct hamartoma (von Meyenburg complex) with which this tumor shares morphologic similarity, suggests that biliary adenofibroma originates from interlobular or larger bile ducts. (thedoctorsdoctor.com)
- However, given the marked nuclear p53 immunoreactivity and tetraploidy status observed in this tumor, we cannot exclude that biliary adenofibroma may represent a premalignant process that warrants complete resection and thorough histopathologic examination. (thedoctorsdoctor.com)
- n. adenomioma, tumor benigno visto con frecuencia en el útero. (thefreedictionary.com)
- Biliary adenofibroma is a rare tumor with a bile duct origin characterized by a complex tubulocystic non-mucin secreting biliary epithelium with abundant fibrous stroma. (bvsalud.org)
- A well-circumscribed multicystic tumor with septal enhancement and no intrahepatic bile duct communication may be the characteristic MRI findings of biliary adenofibroma. (bvsalud.org)
- Cystadenoma, adenofibroma, and surface papillomas are the benign serous tumors. (hindawi.com)
- The previous documentation of BRAF exon 15 mutations in 88% of metanephric adenomas and in isolated cases of metanephric adenofibroma prompted us to investigate the prevalence of these mutations in MSTs and in other pediatric renal stromal tumors. (luriechildrens.org)
- Adenofibroma, also known as adenofibroma, no icd-o subtype , is related to clear cell adenofibroma and cystadenofibroma . (malacards.org)
- metanephric adenofibroma, it was recognized that a separate subset of renal neoplasms consisted entirely of stromal elements identical to the stromal component of metanephric adenofibroma. (bostwicklaboratories.com)
- We report a case of biliary adenofibroma in a 47-year-old woman, who presented with right upper quadrant pain for several months. (thedoctorsdoctor.com)
- The MRI features of biliary adenofibroma are not well established. (bvsalud.org)
- The authors encountered two patients with biliary adenofibroma and reviewed the literature focusing on the MRI findings. (bvsalud.org)
- Carcinosarcoma arising from adenofibroma of the uterus has never been reported in the English literature. (currentmedicalimagingreviews.com)
- La primera adhesión, ocurre entre el sinciciotrofoblasto y las células epiteliales de la pared antimesometrial antes de que ocurra una modificación epitelial general y del tejido conjuntivo subyacente, con aumento de glicógeno y glicosaminoglicanos Resumen en inglés Embryo implantation in mammalian uterus starts by a cell-to-cell direct contact between the blastocyst's trophoblast and the uterine ephitelium. (worldwidescience.org)
- Infiltration by neaplastic tissue or hemorrhage can also be causes of A.D.) Always use Adrenacortical hormone therapy plus: Invive - 2 tsp per day ADENOFIBROMA: (Often caused by staph infection in uterus or breast) Invive - 2 tsp per day for 3 to 6 months ADENOIDITIS Invive - 2 tsp in 3 oz of water, gargle and then swallow liquid b.i.d. also Ag-Cream - place approx. (xpressnet.com)
- An important gene associated with Adenofibroma is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways is Cytoskeletal Signaling . (malacards.org)
- Mediastinal adenofibroma: a case report. (semanticscholar.org)
- What is the treatment of adenofibroma in the breast? (healthtap.com)
- Metanephric adenofibroma and related lesions: Clinicopathologic study of 24 cases. (spponline.org)